Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.22.4
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Research and development expenses $ 2,343,154 $ 1,081,705 $ 6,539,948 $ 1,988,450
General and administrative expenses 1,653,072 1,151,542 4,341,880 2,798,766
Ratchet share expense 1,099,360   1,099,360  
Operating Costs and Expenses, Total 5,095,586 2,233,247 11,981,188 4,787,216
Loss from operations (5,095,586) (2,233,247) (11,981,188) (4,787,216)
Other income (expense):        
Interest expense (1,716) (451,306) (1,820) (827,539)
Interest income 348 708 1,249 1,501
Australian research and development incentives 65,111   230,188  
Change in fair value of embedded features   (96,000)   (203,000)
Change in fair value of warrant liability 128,030 (100,780) 128,030 (1,546,280)
Loss on extinguishment of convertible notes and convertible notes, related parties   (2,322,943)   (2,322,943)
Other income (expense), net 191,773 (2,970,321) 357,647 (4,898,261)
Net loss (4,903,813) (5,203,568) (11,623,541) (9,685,477)
Net loss attributable to noncontrolling interests   (7,130)   (74,331)
Deemed dividend on warrant modification     (450,578)  
Net loss attributable to MAIA Biotechnology, Inc. shareholders $ (4,903,813) $ (5,196,438) $ (12,074,119) $ (9,611,146)
Net loss per share        
Net loss per share basic $ (0.48) $ (1.02) $ (1.39) $ (2.06)
Net loss per share diluted $ (0.48) $ (1.02) $ (1.39) $ (2.06)
Weighted average common shares outstanding basic 10,165,622 5,119,121 8,713,570 4,668,635
Weighted average common shares outstanding diluted 10,165,622 5,119,121 8,713,570 4,668,635